About plus therapeutics inc. - PSTV
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.
PSTV At a Glance
Plus Therapeutics, Inc.
2710 Reed Road
Houston, Texas 77051
| Phone | 1-210-974-6900 | Revenue | 5.21M | |
| Industry | Pharmaceuticals: Major | Net Income | -22,386,000.00 | |
| Sector | Health Technology | Employees | 28 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
PSTV Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 7.646 |
| Price to Book Ratio | 17.779 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.856 |
| Enterprise Value to Sales | 5.288 |
| Total Debt to Enterprise Value | 0.03 |
PSTV Efficiency
| Revenue/Employee | 186,178.571 |
| Income Per Employee | -799,500.00 |
| Receivables Turnover | 16.189 |
| Total Asset Turnover | 0.454 |
PSTV Liquidity
| Current Ratio | 1.20 |
| Quick Ratio | 1.20 |
| Cash Ratio | 1.065 |
PSTV Profitability
| Gross Margin | 91.464 |
| Operating Margin | -293.459 |
| Pretax Margin | -429.426 |
| Net Margin | -429.426 |
| Return on Assets | -195.017 |
| Return on Equity | N/A |
| Return on Total Capital | -464.729 |
| Return on Invested Capital | N/A |
PSTV Capital Structure
| Total Debt to Total Equity | 20.546 |
| Total Debt to Total Capital | 17.044 |
| Total Debt to Total Assets | 5.029 |
| Long-Term Debt to Equity | 0.375 |
| Long-Term Debt to Total Capital | 0.311 |